Table 3B: Overall survival in relation to OC use, stratified by age at diagnosis.

 

n

HR crude (95% CI)

d/m

HR adjustedc (95% CI)

d/m

HR adjustedd (95% CI)

d/m

41-55

116

 

24/0

 

23/1

 

19/48

OC never

30

1.00

8/0

1.00

8/0

1.00

7/15

OC ever

86

0.68 (0.29-1.59)

16/0

0.72 (0.30-1.74)

15/1

0.72 (0.22-2.30)

12/33

56-70

471

 

101/0

 

98/5

 

55/ 223

OC never

204

1.00

49/0

1.00

49/1

1.00

32/96

OC ever

267

0.96 (0.65-1.42)

52/0

0.90 (0.60-1.34)

49/4

0.72 (0.41-1.25)

23/127

71-

177

 

65/0

 

64/3

 

33/80

OC never

130

1.00

58/0

1.00

57/3

1.00

30/59

OC ever

47

0.33 (0.15-0.72)*

7/0

0.34 (0.16-0.76)*

7/0

0.38 (0.11-1.30)

3/21

 

 

 

 

 

 

 

 

 

 

 

 

 

N(number) stands for total cases included in the analysis, d for total deaths in analyses and m for missing data.

 

cAdjusted for BMI, and socioeconomic status

dAdjusted for BMI, socioeconomic status, size of tumor, lymphnod einvolvement, grade of tumor (according to Nottingham), PgR, ER, HER2, P27, Ki67.

*Significance. Confidence interval separate from 1.00